2 weeks Ago By ABMN Staff
Certara, Inc. ( NASDAQ:CERT – Get Free Report )’s stock price gapped up before the market opened on Friday . The stock had previously closed at $10.
70, but opened at $11.59. Certara shares last traded at $11.
74, with a volume of 140,900 shares traded. Analyst Upgrades and Downgrades CERT has been the topic of a number of recent analyst reports. Barclays cut their price objective on Certara from $18.
00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. Robert W.
Baird dropped their target price on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th.
UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday. KeyCorp cut their target price on Certara from $23.
00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, JMP Securities reissued a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th.
Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $17.
79. Get Our Latest Stock Analysis on CERT Certara Stock Performance Certara ( NASDAQ:CERT – Get Free Report ) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.
07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03).
The firm had revenue of $93.31 million for the quarter, compared to analysts’ expectations of $96.01 million.
Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%.
The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.
10 earnings per share. As a group, analysts anticipate that Certara, Inc. will post 0.
27 earnings per share for the current year. Insider Buying and Selling at Certara In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th.
The stock was sold at an average price of $11.29, for a total transaction of $578,318.96.
Following the sale, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website .
Corporate insiders own 2.39% of the company’s stock. Institutional Trading of Certara A number of large investors have recently bought and sold shares of the company.
Norges Bank purchased a new position in shares of Certara in the fourth quarter worth about $14,262,000. Evoke Wealth LLC bought a new position in shares of Certara in the fourth quarter worth $1,723,000. Premier Fund Managers Ltd raised its stake in shares of Certara by 87.
5% during the 4th quarter. Premier Fund Managers Ltd now owns 16,553 shares of the company’s stock valued at $296,000 after purchasing an additional 7,727 shares during the period. Scout Investments Inc.
boosted its stake in Certara by 18.9% in the 4th quarter. Scout Investments Inc.
now owns 368,790 shares of the company’s stock worth $6,487,000 after purchasing an additional 58,746 shares during the period. Finally, Wasatch Advisors LP grew its holdings in Certara by 22.7% during the 4th quarter.
Wasatch Advisors LP now owns 3,992,247 shares of the company’s stock valued at $70,224,000 after buying an additional 737,982 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.
About Certara ( Get Free Report ) Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. Read More Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.
com's FREE daily email newsletter ..
